ReviewIntestinal research2021
Management of Clostridioides difficile infection in patients with inflammatory bowel disease.
Review in Intestinal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis.World journal of pediatrics : WJP · 2022Pooled it
- Diagnostic challenges and treatment approaches forFrontiers in microbiology · 2026Review
- Clinical characteristics and risk factors analysis ofFrontiers in cellular and infection microbiology · 2026Article
- Addressing Unmet Needs inCurrent medicinal chemistry · 2026Review
- Proton pump inhibitors and the risk of hospital acquired clostridioides difficile infection in critically ill patients.Frontiers in pharmacology · 2026Article
- Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study.Gut pathogens · 2025Article
- Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review.Journal of clinical medicine · 2025Review
- Recurrent Clostridium difficile Infections in a Patient With Ulcerative Colitis: A Case Report.Cureus · 2025Article
- Discordance in Clinical Indicators With Sequential Fecal Microbiota Transplantation: A Case of FulminantACG case reports journal · 2025Article
- Higher disease activity of inflammatory bowel disease predisposes toTherapeutic advances in gastroenterology · 2025Article
- Management of Clostridioides difficile infection: an Italian Delphi consensus.The Journal of antimicrobial chemotherapy · 2024Article
- Special Issue "Bacterial Toxins and Cancer".International journal of molecular sciences · 2024Article
- Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system.Frontiers in immunology · 2024Review
- Gut Microbiota Associated withMicroorganisms · 2023Article
- Review
- Review
- Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Review
- Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah.Interdisciplinary perspectives on infectious diseases · 2023Article
- Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a common diarrheal illness with gastrointestinal and extraintestinal manifestations and complications. The most common infectious complication associated with IBD is Clostridioides difficile infection (CDI). Active IBD predisposes to CDI due to alterations in the gut microbiome. C. difficile is a toxin producing bacterium leading to worsening of underlying IBD, increasing the risk of IBD treatment failure and an increased risk of hospitalization and surgery. Since the symptoms of CDI overlap with those of an IBD flare; it is prudent to recognize that the diagnosis of CDI is challenging and diagnostic tests (nucleic-acid and toxin-based assays) should be interpreted in context of symptoms and test performance. First line treatments for management of CDI in IBD include vancomycin or fidaxomicin. Recurrence prevention strategies should be implemented to mitigate recurrent CDI risk. One needs to monitor IBD disease progression and manage immunosuppression. The risk of recurrent CDI after a primary infection is higher in IBD compared to non-IBD patients. Microbiota restoration therapies are effective to prevent recurrent CDI in IBD patients. This review summarizes the epidemiology, pathophysiology, diagnostic testing, outcomes and management of both CDI and IBD, in CDI complicating IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.